Filing Signals

Source: SEC EDGAR Compiled 2026-11-14 10:32 UTC 23 automated checks passing

← All events

VITASPRING BIOMEDICAL CO. LTD.

CIK 1697884 VSBC·Commercial Physical And Biological Research · All EDGAR filings ↗

Progression

  1. Material weakness 10-Q
  2. Revenue recognition change 10-K +146d
  3. Finance chief departure 8-K +94d
  4. Going concern 10-Q +7d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Going concern Filing comparison

VITASPRING BIOMEDICAL CO. LTD. said management's plans alleviate substantial doubt about going concern

Substantial doubt about ability to continue as a going concern → Substantial doubt raised, alleviated by management's plans

The Company incurred a net loss of $231,661 and positive cash flows from operating activities of $11,283 for the six months ended July 31, 2026. The Company also has an accumulated deficit of $5,928,532 as of July 31, 2026. The Company’s minimal cash balance, recurring operating losses, and significant working capital deficit raise substantial doubt about its ability to continue as a going concern within one year after the financial statements are issued. The Company has historically financed its operations through advances from related parties and equity issuances. Management plans to…
Evidence
Blank check
No
Comparable
Yes
Current state
doubt_alleviated
Current state label
Substantial doubt raised, alleviated by management's plans
Direction
eased
Located in
going-concern note
Prior filed
2026-06-17
Prior form
10-Q
Prior state
substantial_doubt
Prior state label
Substantial doubt about ability to continue as a going concern
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.

Source filing ↗ Prior filing ↗

Late filing elevated Filing comparison

VITASPRING BIOMEDICAL CO. LTD. filed its quarterly report late and said it expects a significant change in results

expects significant change in results 1 day past the statutory due date.

Evidence
Anticipates significant change
Yes
Days past due date
1
Other periodic reports filed
Yes
Routine
No
Severity
elevated
Source
Form 12b-25 (notification of late filing)
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗

Finance chief departure high Filing comparison

VITASPRING BIOMEDICAL CO. LTD.'s Chief Financial Officer departed with no named successor

Evidence
Interim only
No
Item code
5.02
Item title
Departure of Directors or Certain Officers
Role
Chief Financial Officer
Severity
high
Source
SEC 8-K item code
Successor named
No
Why
The company's chief financial or accounting officer departed, disclosed under 8-K Item 5.02.

Source filing ↗

Revenue recognition change beta Filing comparison

VITASPRING BIOMEDICAL CO. LTD. changed its revenue recognition disclosure

The Company recognizes revenues when satisfying the performance obligation of the associated contract that reflects the consideration expected to be received based on the terms of the contract.
Evidence
New language
The Company recognizes revenues when satisfying the performance obligation of the associated contract that reflects the consideration expected to be received based on the terms of the contract., (v) Recognize revenue when the Company satisfies a performance obligation.
Prior filed
2026-05-06
Prior form
10-Q
Similarity
0.471
Source
revenue recognition note comparison
Threshold
0.6
Why
The revenue recognition policy disclosure changed materially from the previous comparable filing.

Language present now, absent from the prior filing:

  • The Company recognizes revenues when satisfying the performance obligation of the associated contract that reflects the consideration expected to be received based on the terms of the contract.
  • (v) Recognize revenue when the Company satisfies a performance obligation.

Source filing ↗ Prior filing ↗

Revenue recognition change beta Filing comparison

VITASPRING BIOMEDICAL CO. LTD. changed its revenue recognition disclosure

The Company recognizes revenues when satisfying the performance obligation of the associated contract that reflects the consideration expected to be received based on the terms of the contract.
Evidence
New language
The Company recognizes revenues when satisfying the performance obligation of the associated contract that reflects the consideration expected to be received based on the terms of the contract., (v) Recognize revenue when the Company satisfies a performance obligation.
Prior filed
2026-03-12
Prior form
10-K
Similarity
0.515
Source
revenue recognition note comparison
Threshold
0.6
Why
The revenue recognition policy disclosure changed materially from the previous comparable filing.

Language present now, absent from the prior filing:

  • The Company recognizes revenues when satisfying the performance obligation of the associated contract that reflects the consideration expected to be received based on the terms of the contract.
  • (v) Recognize revenue when the Company satisfies a performance obligation.

Source filing ↗ Prior filing ↗

Material weakness high Filing comparison

VITASPRING BIOMEDICAL CO. LTD. reported a material weakness in internal control

Internal control reported effective → Material weakness in internal control

GAAP and SEC reporting requirements. This deficiency increased the risk of material misstatements in the financial reporting process. Remediation Plan We are committed to improving our internal control environment. To remediate the identified material weakness, we plan to evaluate and enhance our internal control procedures and, as resources permit, hire additional qualified personnel or engage external consultants with relevant expertise in financial reporting and SEC compliance. We intend to enhance our internal…
Evidence
Current state
material_weakness
Current state label
Material weakness in internal control
Direction
newly reported
Prior filed
2022-12-21
Prior form
10-Q
Prior state
effective
Prior state label
Internal control reported effective
Remediation stated
Yes
Severity
high
Source
Item 9A internal control conclusion, compared with the prior filing
Why
The company's conclusion on internal control over financial reporting changed: a material weakness was newly reported, or a previously reported one no longer appears.

Source filing ↗ Prior filing ↗